close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

780.50 -4.47 (-0.57%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 545,095
Open 780.56
Bid (Size) 774.00 (480)
Ask (Size) 783.00 (520)
Prev. Close 784.97
Today's Range 774.60 - 785.05
52wk Range 476.49 - 792.77
Shares Outstanding 91,779,465
Dividend Yield 0.45%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
3 Cash-Heavy Stocks We Approach with Caution
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow. 
Via StockStory
News headline image
The Vaccine Vanguard: Inside Sanofi’s $2.2 Billion Strategic Bet on Dynavax
As 2025 draws to a close, the global pharmaceutical landscape has been reshaped by a series of aggressive consolidations and strategic pivots. At the center of this transformation is Sanofi (NASDAQ:... 
Via PredictStreet
Topics Artificial Intelligence Economy Intellectual Property

Performance

YTD
+9.1%
+9.1%
1 Month
+0.0%
+0.0%
3 Month
+39.2%
+39.2%
6 Month
+48.7%
+48.7%
1 Year
+11.1%
+11.1%

More News

Read More
News headline image
The Atomic Architect: How University of Washington’s Generative AI Just Rewrote the Rules of Medicine
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Sanofi’s $2.2 Billion Strategic Pivot: Deconstructing the Dynavax Acquisition and the Future of Specialty Medicine
Via PredictStreet
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
AbbVie, Merck, Other Top Drugmakers To Lower Prices Of US Drugs In MFN Deal With Trump Administration: Report ↗
Via Stocktwits
Topics Economy Government
News headline image
Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗
Via Stocktwits
Topics Government World Trade
News headline image
Pfizer Adds to Its Big Bet on Weight Loss Drugs ↗
Via MarketBeat
News headline image
2 Large-Cap Stocks on Our Buy List and 1 We Find Risky
Via StockStory
News headline image
2 Reasons to Buy Regeneron Stock Like There's No Tomorrow ↗
Via The Motley Fool
News headline image
Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
News headline image
3 Low-Volatility Stocks We’re Skeptical Of
Via StockStory
News headline image
Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Is Alnylam Pharmaceuticals a Millionaire Maker? ↗
Via The Motley Fool
News headline image
3 Cash-Producing Stocks We Find Risky
Via StockStory
News headline image
Morgan Stanley Downgrades Regeneron (REGN) to Equal-Weight, Citing Fair Valuation and Pipeline Scrutiny
Via MarketMinute
Topics Intellectual Property
News headline image
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
5 Healthcare Names to Watch as Sector Rotation Is in Full Swing ↗
Via MarketBeat
News headline image
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Should You Buy This Biotech Stock That Just Gained 5% in 1 Day? ↗
Via The Motley Fool
News headline image
Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
1 Reason Why Shares of Regeneron Pharmaceuticals Are Surging This Month ↗
Via The Motley Fool
News headline image
Mettler-Toledo, Agilent, Waters Corporation, Merck, and Regeneron Shares Skyrocket, What You Need To Know
Via StockStory
Topics Economy World Trade
News headline image
3 Nasdaq 100 Stocks We Keep Off Our Radar
Via StockStory

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?
Yes, Regeneron Pharmaceuticals is publicly traded.
What exchange does Regeneron Pharmaceuticals trade on?
Regeneron Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Regeneron Pharmaceuticals?
The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market
What is the current price of Regeneron Pharmaceuticals?
The current price of Regeneron Pharmaceuticals is 780.50
When was Regeneron Pharmaceuticals last traded?
The last trade of Regeneron Pharmaceuticals was at 12/29/25 04:00 PM ET
What is the market capitalization of Regeneron Pharmaceuticals?
The market capitalization of Regeneron Pharmaceuticals is 71.63B
How many shares of Regeneron Pharmaceuticals are outstanding?
Regeneron Pharmaceuticals has 72B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today